Investors in Edwards Lifesciences Corporation (EW) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $45.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. ...

Edwards Lifesciences (EW) , following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the differentiated PASCAL technology is highly promising. The company is also advancing toward long-term growth through several initiatives across its businesses. Meanwhile, adverse macroeconomic impacts and currency fluctuations remain a concern for Edwards.In the past year, this Zacks Rank #3 (Hold) stock has dropped 1. ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 12, 2024 /PRNewswire ...

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”), have until this upcoming Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences ...

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=115935&from=4 CLASS PERIOD: Febr ...

RADNOR, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

RADNOR, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=114502&from=3 CLASS PERIO ...

Core Insights - Edwards Lifesciences Corporation is focused on long-term growth and innovation in structural heart therapies, particularly in TAVR and TMTT [1][2] - The company anticipates strong sales growth in 2025, projecting an increase of 8% to 10% driven by advancements in its technologies [2][5] Growth Drivers - TAVR is expected to generate sales of $4.1 to $4.4 billion in 2025, with a constant currency growth rate of 5% to 7% [4] - TMTT is forecasted to grow by 50% to 60% in 2025, with projected sales of $500 to $530 million [4] - New technologies like the EVOQUE tricuspid valve and PASCAL system are crucial for growth, alongside anticipated regulatory approvals for SAPIEN M3 [4] - The company aims for an average annual sales growth of 10% and double-digit EPS growth starting in 2026, driven by its expanding range of structural heart therapies [4] Financial Outlook - Edwards projects total sales for 2025 to be between $5.6 billion and $6 billion, slightly below the consensus of $5.91 billion [5] - Adjusted earnings per share are expected to be in the range of $2.40 to $2.50, compared to the consensus of $2.44, with gross profit margins of 78% to 79% [5] Market Performance - Edwards Lifesciences' stock increased by 4.21%, reaching $73.15 [6]